42nd week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210322357 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids - A method of treating medium chain acyl-CoA dehydrogenase deficiency, very long chain acyl-CoA dehydrogenase deficiency, long chain hydroxyacyl-CoA dehydrogenase deficiency, trifunctional protein deficiency, or CPT II deficiency in a patient is provided comprising administering to the patient a therapeutic amount of a triglyceride or other conjugated fatty acid, that bypasses or leads to an intermediate that bypasses the deficient enzyme. Amino acid-conjugated fatty acids also are provided as well as compositions comprising the amino acid-conjugated fatty acids. | 2021-10-21 |
20210322358 | Method for Treating Lysosomal Storage Disease - This application is directed to the use of a ketogenic agent, such as 1,3-butanediol, R-β-hydroxybutyl-R-β-hydroxybutyrate, or triheptanoin, in the treatment of an individual having a lysosomal storage disease, including Pompe disease. Compositions comprising ketogenic agents and metabolic enhancing agents for treating a lysosomal storage disease are also provided. | 2021-10-21 |
20210322359 | SICKLE CELL DISEASE TREATMENT UTILIZING OMEGA-3 FATTY ACIDS - Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration. | 2021-10-21 |
20210322360 | SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES - Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration. | 2021-10-21 |
20210322361 | METHOD OF PREVENTING OR TREATING SIDE EFFECT OF TUMOR THERAPY - The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject. The mothed comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent. | 2021-10-21 |
20210322362 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS - This disclosure provides compounds of Formula (I) | 2021-10-21 |
20210322363 | METHODS OF INDUCING ANESTHESIA - The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods. | 2021-10-21 |
20210322364 | TOPICAL FORMULATIONS AND METHODS OF USE THEREOF - Provided herein are topical pharmaceutical compositions comprising lidocaine or a pharmaceutically acceptable salt thereof, capsaicin, and hemp oil and methods of using the topical pharmaceutical compositions to treat neuropathic and nociceptive pain. | 2021-10-21 |
20210322365 | POLYCANNABINOIDS, COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Polymers comprising a plurality of cannabinoids, methods of preparation thereof, and methods of use to treat a number of disease conditions are reported. Also provided are polymer coatings, films, fibers, and non-woven fabrics for a variety of topical applications including stents, bandages, sutures, and transdermal patches. | 2021-10-21 |
20210322366 | HERBAL PREPARATION-ENRICHED CANNABINOID COMPOSITION AND METHODS OF TREATMENT - A method of treatment including administering to a subject in need a therapeutically effective amount of a product having (i) at least one cannabinoid, (ii) at least one herbal preparation, where the herbal preparation is produced by at least one of distilling and extracting a portion of a plant, where the plant is not | 2021-10-21 |
20210322367 | ISOLATED OR SYNTHETIC CANNABINOID COMPOSITIONS WITH SELECTED TERPENE BLEND AND METHODS OF USE THEREOF - A method of treatment comprising administering to a subject in need thereof a therapeutically effective amount of a product including (i) at least one isolated or synthetic cannabinoid, where at least a fraction of said isolated or synthetic cannabinoid is obtained by a process selected from the group consisting of processing hemp, chemical synthesis, biological synthesis, isolation from a plant source, crystallization and combinations thereof, (ii) optionally, at least one other cannabinoid, (iii) at least one primary terpene, and (iv) optionally at least three secondary terpenes. | 2021-10-21 |
20210322368 | SOLID DOSAGE FORM COMPOSITION FOR BUCCAL OR SUBLINGUAL ADMINISTRATION OF CANNABINOIDS - The present invention relates to solid dosage forms of cannabinoid pharmaceutical formulations comprising a solvated cannabinoid for buccal or sublingual administration, and methods of making and using the same. | 2021-10-21 |
20210322369 | COMPOSITION FOR IMPROVING INTESTINAL ENVIRONMENT AND METHOD FOR IMPROVING INTESTINAL FLORA - The present invention aims to provide a novel composition for improving gut flora and a method of improving gut flora, capable of increasing the abundance ratio of probiotics in the gut flora. The present invention relates to, for example, a composition for improving gut flora containing isoxanthohumol and/or xanthohumol as an active ingredient. | 2021-10-21 |
20210322370 | COMPOSITIONS FOR THE MANAGEMENT OF SEIZURE INDUCED NEUROTOXICITY - The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use reducing the incidence of seizures and in the management of neurotoxicity induced by seizures. | 2021-10-21 |
20210322371 | NANOSIZED CAROTENOID CYCLODEXTRIN COMPLEXES - Methods for the preparation of nanosized nutrient formulations for enhanced absorption of nutritional agents. The methods include the complexation of cyclodextrin with carotenoids and incorporation of the complexes into the nutritional supplements without intermediate collection, isolation, and drying steps. | 2021-10-21 |
20210322372 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS - The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents. | 2021-10-21 |
20210322373 | Compositions and Methods for the Treatment of Metabolic Conditions - The present invention relates to stable therapeutic compositions of pharmaceutical grade acids and pH buffering agents. The present invention also is directed to methods of treatment for mitochondrial disorders, metabolic conditions, diabetic conditions, and cardiovascular conditions, by administration of compositions of the present disclosure. | 2021-10-21 |
20210322374 | COMPOSITIONS AND METHODS FOR PAIN RELIEF - The invention provides pharmaceutical compositions having improved effects and synergistic efficacy against pain, and provides methods for their use to treat pain, wherein the composition comprises: a sulfur-containing amino acid; a carnitine compound; and at least one compound that is a L-citrulline compound or a beta-alanine compound. | 2021-10-21 |
20210322375 | COMBINATION DRUG FORMULATIONS FOR TREATING PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS - Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject. | 2021-10-21 |
20210322376 | METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES - Disclosed herein are compositions comprising fixed doses of ETC-1002, ezetimibe, and statin, and methods of treating subjects comprising administering fixed doses of ETC-1002, ezetimibe, and statin. Also disclosed herein are methods for administering fixed doses of ETC-1002 or ezetimibe or both to statin-intolerant patients or patients receiving statin therapy, wherein the administration reduces the likelihood of worsening diabetes in the subject or increasing the likelihood of new onset diabetes in a subject. The methods disclosed herein also include methods of treating hypercholesterolemia and cardiovascular diseases in a subject. | 2021-10-21 |
20210322377 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a). | 2021-10-21 |
20210322378 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a). | 2021-10-21 |
20210322379 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, budesonide, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a). | 2021-10-21 |
20210322380 | COMBINATION DRUG - The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth. | 2021-10-21 |
20210322381 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG - A drug used for treating or preventing cerebral hemorrhage, the drug including, as an active ingredient, a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof: | 2021-10-21 |
20210322382 | METHODS AND COMPOSITIONS FOR IMPROVED TREATMENT OF SINUS DISEASE - Compositions for treating, controlling, reducing, or inhibiting a chronic established biofilm in a sinus of a human when applied topically or through irrigation is disclosed. Methods for treating a subject with a bacterial infection or a SARS-CoV-2 infection using a disclosed composition as disclosed, the composition comprising 0.5 wt %-2.5 wt % povidone-iodine; 0.15 wt %-1.25 wt % hydroxyethylcellulose; and water. | 2021-10-21 |
20210322383 | NEUROPROTECTIVE DISRUPTION OF KV2.1/SYNTAXIN INTERACTION BY SMALL MOLECULES - Disclosed herein are small molecule compounds capable of disrupting Kv2.1-syntaxin binding. The compounds are useful for treating a variety of neurological disorders, diseases, and injuries. | 2021-10-21 |
20210322384 | Method of Treatment for Ketamine Infusion - Methods for treatment for patients having depression and/or pain are contemplated as including an administration of first preparation comprising an antiemetic agent, preferably ondansetron, followed by a second preparation of a synergistic combination of ketamine and a benzodiazepine, preferably lorazepam, administered via a continuous intravenous infusion. Such methods may be seen to better alleviate depression and pain symptoms, and may result in reduced need for other medications. | 2021-10-21 |
20210322385 | MEDICINAL PREPARATION FOR EXTERNAL USE - The present invention pertains to a drug for the treatment and/or prevention of pain, more specifically to a medicinal preparation for external use to treat and/or prevent peripheral neuropathic pain, the medicinal preparation containing as an active ingredient N | 2021-10-21 |
20210322386 | METHODS OF DELAYING AND REVERSING ALZHEIMER'S DISEASE PROGRESSION - In one aspect, methods of reversing or delaying the progression of Alzheimer's disease in a subject having Alzheimer's disease or delaying the onset of Alzheimer's disease in a subject having mild cognitive impairment are provided. In some embodiments, the method comprises administering to the subject an oxysterol inhibitor. | 2021-10-21 |
20210322387 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed. | 2021-10-21 |
20210322388 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2021-10-21 |
20210322389 | METHODS AND COMPOSITIONS FOR TREATING SEPSIS - In an aspect, the invention relates to compositions and methods for treating sepsis, including but not limited neonatal sepsis and sepsis related to infection. In an aspect, the invention relates to compositions and methods for attenuating adverse conditions of sepsis resulting from enterovirus infection. In an aspect, the invention relates to improved formulations of antiviral agents such as pleconaril for the treatment, alleviation and prevention of conditions associated with sepsis. | 2021-10-21 |
20210322390 | SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION - The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection. | 2021-10-21 |
20210322391 | METHODS OF TREATING EPITHELIOID CELL TUMORS - The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin. | 2021-10-21 |
20210322392 | Low Concentration Delivery of an Ergoline Derivative for Treatment of a Headache - Provided are ergoline derivative containing medicaments disposed within a preassembled, prefilled, single-use delivery device, methods for administering a medicament using a preassembled, prefilled, single-use delivery device, and systems or kits that contain one or more preassembled, prefilled, single-use devices and user instructions, such as for treatment of a migraine or other headache. | 2021-10-21 |
20210322393 | METHODS OF TREATING COGNITIVE IMPAIRMENT ASSOCIATED WITH NEURODEGENERATIVE DISEASE - Provided herein are methods of treating cognitive impairment associated with neurodegenerative disease in a patient by administering to the patient an effective amount of the Compound, or a pharmaceutically acceptable salt thereof. | 2021-10-21 |
20210322394 | TREATMENT OF INFECTIONS AND BIOFILM FORMATION USING A CELLULOSE SYNTHASE INHIBITOR - In one embodiment, the present application relates to methods and materials for weed control of a field of a crop plant using a cellulose biosynthesis inhibitor selected from the group consisting of ES20 and ES20-1 to ES20-9 of FIG. | 2021-10-21 |
20210322395 | METHOD TO PREVENT AND TREAT HEARING LOSS BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS - A method is provided to prevent and to treat hearing loss by using Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or Angiotensin Receptor Blockers (ARB), and more particularly, to a method to prevent and treat hearing loss by using Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, or Angiotensin Receptor Blockers that are not taken orally, but administered topically or by injection, so as to increase the capillary network and blood supply to the affected tissues, e.g., through to the external ear space and/or the middle ear space and/or the inner ear space to form contact with the ear hearing apparatus. | 2021-10-21 |
20210322396 | COMPOSITIONS WITH SYNERGISTIC PERMEATION ENHANCERS FOR DRUG DELIVERY - The present disclosure provides compositions and methods for delivery of therapeutic agents across a barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent, wherein the composition comprises between about 0.5-5.0% wt/vol of a permeation enhancer that is sodium dodecyl sulfate; wherein the compositions comprise between about 0.5-2.5% wt/vol of a permeation enhancer that is bupivacaine; wherein the compositions comprise between about 1.5-12.0% wt/vol of a permeation enhancer that is limonene; and wherein the compositions comprise between about 9.0-19.0% wt/vol of a polymer that is poloxamer 407-poly(butoxy)phosphoester; and optionally further comprises between about 0.01-0.50% wt/vol of another therapeutic agent that is a sodium channel blocker anesthetic agent (e.g., tetrodotoxin). | 2021-10-21 |
20210322397 | METHOD TO PREVENT AND TREAT GINGIVAL RECESSION BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS - A method is provided to prevent and to treat gingival recession by using Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or Angiotensin Receptor Blockers (ARB), and more particularly, to a method to prevent and treat gingival recession, e.g., age related gingival recession, by using Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, or Angiotensin Receptor Blockers that are not taken orally, but administered by injection into the affected tissue or administered by topical application to the tissue of the gum, so as to increase the capillary network and blood supply to the cartilage, bones, ligaments, and soft tissues. | 2021-10-21 |
20210322398 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; methods of using the composition to inhibit neoplastic cell growth in mammals, including humans. | 2021-10-21 |
20210322399 | TREATMENT OF SCHIZOPHRENIA - Aspects of the invention relate generally to the treatment of schizophrenia and to monitoring for specific adverse reactions. | 2021-10-21 |
20210322400 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation - The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy. | 2021-10-21 |
20210322401 | COMPOUNDS AND CONJUGATES THEREOF - A conjugate comprising the following topoisomerase inhibitor derivative (A*): | 2021-10-21 |
20210322402 | COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS - The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. | 2021-10-21 |
20210322403 | SUBLINGUAL APOMORPHINE - The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith. | 2021-10-21 |
20210322404 | FGFR REGULATION FOR THE TREATMENT OF VIRAL INFECTIONS - The present invention is directed to a compound for inhibiting (i) FGF-R kinase activity or (ii) a component of the FGFR kinase signaling pathway for use in the therapeutic or prophylactic treatment of viral infections as well as corresponding pharmaceutical compositions for use in the same treatment and related methods of treatment. | 2021-10-21 |
20210322405 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present disclosure provides for compositions and methods of treating cancer. In some embodiments, PTPN11 is targeted with and anti-PTPN11 drug, such as a Shp2 inhibitor (e.g., SHP099). In some embodiments, other upregulated, hyperphosphorylated, or hyperacetylated target proteins are inhibited or targeted. | 2021-10-21 |
20210322406 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2021-10-21 |
20210322407 | Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases - This present invention discloses a new use of trimetazidine as a hepatoprotective drug in prevention and treatment of liver diseases, wherein trimetazidine is capable of inhibiting activation of resting T lymphocytes to activated lymphocytes, reducing release of cytokines, and reducing the hepatocyte injury caused by the immune system; capable of inhibiting fatty acid metabolism in hepatocytes and optimizing energy process in hepatocytes; and capable of maintaining normal function of mitochondrial permeability transition pores and reducing hepatocyte apoptosis. Clinical research and trial results suggest that, when administered to patients suffering from liver diseases and conditions, trimetazidine is capable of providing significant hepatoprotective function, and effectively decreasing transaminase levels (including alanine aminotransferase, aspartate transaminase, etc.), with such features as shortening the course of disease, reducing the mortality rate, easy and safe use, and low treatment cost. Trimetazidine is eliminated unchanged mainly through urine, with the elimination half-life of approximately 6 hours, and without hepatic metabolism. Therefore, trimetazidine has minimal liver toxicity, while having significant hepatoprotective effect. | 2021-10-21 |
20210322408 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate - In an embodiment, therapeutic methods and uses of Bruton's Tyrosine Kinase (BTK) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a BTK inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. | 2021-10-21 |
20210322409 | METALLOENZYME INHIBITOR COMPOUNDS - Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. | 2021-10-21 |
20210322410 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES - Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody. | 2021-10-21 |
20210322411 | ANALOGS OF 3,5-DIHYDROXYPENTANOATE FOR BONE FORMATION - A method for treating low bone mineral density associated with osteopenia, osteoporosis, and other diseases is disclosed. The method comprises administrating a composition comprising a 3,5-dihydroxypentanoic acid derivative according to Formula I to a mammal. A compound of 3,5-dihydroxypentanoic acid derivative having a structure according to Formula I or Formula II is also disclosed. | 2021-10-21 |
20210322412 | METHODS AND COMPOSITIONS FOR TREATING A CORONAVIRUS INFECTION - The invention provides methods, compositions, and kits for using substituted (4-(amino)piperidin-1-yl)(6-(((tetrahydro-2H-pyran-2-yl)methyl)amino)pyrimidin-4-yl)methanone compounds to treat a coronavirus infection and related medical conditions. | 2021-10-21 |
20210322413 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR - The invention relates to nitric oxide releasing phosphodiesterase type 5 (PDE5) inhibitors of formula (I) or (Ib) or (II) or a stereoisomer or a pharmaceutically acceptable salt thereof: | 2021-10-21 |
20210322414 | FFA1 (GPR40) AS A THERAPEUTIC TARGET FOR NEURAL ANGIOGENESIS DISEASES OR DISORDERS - The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided. | 2021-10-21 |
20210322415 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB - Methods comprising repeating cycles of administration of a composition comprising cediranib according to a fixed intermittent dosing regimen comprising administration of an effective amount of the composition comprising cediranib on one or more consecutive days of a cycle followed by one or more consecutive days of rest on which said composition is not administered are disclosed herein, and may be used as monotherapy or may comprise administration of one or more partner drugs or therapies and may be used in combination therapy. Such methods may produce an antiangiogenic and/or vascular permeability reducing effect, treat at least one disease state associated with angiogenesis, reduce the total dose of cediranib required to provide effective VEGF inhibition, reduce adverse events and toxicity due to cediranib administration, maintain cover on the VEGF pathway despite reduction of total doses of cediranib, and/or increase repair of healthy, non-cancerous tissue during treatment of cancer using combination therapies. | 2021-10-21 |
20210322416 | ANTIVIRAL COMPOUNDS - The invention provides a compound of formula I, formula II, or formula III: | 2021-10-21 |
20210322417 | GASTRIC CANCER TREATMENTS - Provided herein, in some embodiments, are methods, compositions, and kits for treating lapatinib-resistant gastric cancer. | 2021-10-21 |
20210322418 | METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING IN A SUBJECT SUFFERING FROM ECTODERMAL DYSPLASIAS - The present invention relates to a method for promoting wound healing in a subject suffering from Ectodermal dysplasia in need thereof comprising a step of administering subcutaneously, intradermally or topically to said subject a therapeutically effective amount of a compound which restores the activity of p63. Inventors have performed a primary culture of patient keratinocytes suffering from ectodermal dysplasias with two compounds which restore the activity of p63 (e.g. STIMA-1 and/or PRIMA-1Met). They have shown that there is an important differentiation of the keratinocytes of said patient compared to the cells not treated with these compounds. They observed that the activity of p63 mutated is restored, thus the proliferation and differentiation of keratinocytes from the patient are activated. Moreover, inventors have used PRIMA-1Met by topical application on a young patient suffering from ectodermal dysplasias and shown that said patient presents an improvement on her hand. Typically, severe skin erosions (on hands and feet) are healing when PRIMA-1Met is administered topically on the hand. | 2021-10-21 |
20210322419 | PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE - The present invention relates to a pharmaceutical composition comprising ibrutinib as an effective ingredient for preventing or treating degenerative brain disease. Ibrutinib according to the present invention inhibits the activity of microglias or astrocytes to suppress the damage of activated microglias or activated astrocytes on neurons, exhibits the excellent effect of restraining the lipopolysaccharide (LPS)-induced migration of microglias, has the activity of reducing amyloid plaques and inhibiting the phosphorylation of tau proteins, and enhances memory and learning capability and thus can be used as a therapeutic agent for prevention or treatment of degenerative brain disease | 2021-10-21 |
20210322420 | FUSED HETEROTRICYCLIC ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF - The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject. | 2021-10-21 |
20210322421 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) INFECTION - Disclosed herein are methods for treating an individual having a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The method may comprise administering a JAK inhibitor, for example ruxolitinib (JAKAFI®), to an individual in need thereof, such individual generally being an individual having, or suspecting of having, SARS-CoV-2 infection. The individual in need thereof may be an individual having, or suspected of having or at risk for developing SARS-CoV-2 infection-related cytokine storm. The individual in need thereof may further be an individual having, or suspected of having SARS-CoV-2 infection-related pneumonia. | 2021-10-21 |
20210322422 | USE OF AKT INHIBITORS IN OPHTHALMOLOGY - The present invention provides the use of an Akt inhibitor for the treatment of ocular vascular disease, in particular age-related macular degeneration. | 2021-10-21 |
20210322423 | APPLICATION OF PDE9A INHIBITOR IN PREPARATION OF PRODUCTS HAVING ELEVATED TREG CONTENT, DRUGS FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASE AND HEALTH CARE PRODUCTS - The present invention relates to the field of medicine, and related to an application of a PDE9A inhibitor in the preparation of products having an elevated Treg content, drugs for preventing and treating inflammatory bowel disease, and health care products. The PDE9A inhibitor may improve the secretion of mucosal mucus in an intestinal tract suffering from inflammatory bowel disease, reduce the secretion of TNF-α, IL-6, IL-17 and IL-12/IL-23 pro-inflammatory factors, inhibit DC cell differentiation and migration, increase the ratio Foxp3+Treg cells, promote the movement of CD4+CD25+ Treg cells from the spleen and mesenteric lymph nodes to the colon, thereby inhibiting an intestinal inflammatory response and controlling the occurrence and development of the disease. When PDE9A inhibitor is applied to a drug for preventing and treating inflammatory bowel disease, inflammatory bowel disease may be effectively prevented, alleviated and treated, while healthcare products containing said inhibitor as an active ingredient may regulate the intestinal tract of patients suffering from inflammatory bowel disease and control the occurrence and development of inflammatory bowel disease. | 2021-10-21 |
20210322424 | Finished Pharmaceutical Dosage Form Of A Methenamine Salt Such As Methenamine Mandelate - The present invention contemplates a high dose finished pharmaceutical dosage form comprising a methenamine salt, such as methenamine mandelate, as an active pharmaceutical ingredient wherein the methenamine salt API has a moisture content that is less than the upper limit specified in the USP. A preferred embodiment of the present invention has a moisture content that is half of the limit set forth in the USP for each particular methenamine salt. An even more preferred embodiment has a moisture content of less than or equal to one-tenth of a percent (0.1%), regardless of the methenamine salt. The present invention may include one or more pharmaceutically acceptable ingredients. The present invention also contemplates a moisture content of the high dose finished pharmaceutical dosage form that is less than one percent. | 2021-10-21 |
20210322425 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF - The present invention provides prodrugs and methods of use thereof. | 2021-10-21 |
20210322426 | METHODS OF TREATING CANCER WITH PI3K ALPHA INHIBITORS AND METFORMIN - Described herein are methods of treating PIK | 2021-10-21 |
20210322427 | INHIBITION OF RIP KINASES FOR TREATING NEURODEGENERATIVE DISORDERS - Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders. | 2021-10-21 |
20210322428 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR ITS SALT - The present disclosure provides a pharmaceutical composition for oral administration comprising: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide (Lazertinib) or its pharmaceutically acceptable salt as an active ingredient; and a combination of microcrystalline cellulose and mannitol as a diluent. | 2021-10-21 |
20210322429 | STABILIZED FORMULATIONS OF CNS COMPOUNDS - Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone. | 2021-10-21 |
20210322430 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS - The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH). | 2021-10-21 |
20210322431 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS - The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH). | 2021-10-21 |
20210322432 | SELECTIVE P2X3 MODULATORS - Provided herein are methods for the treatment of avoiding loss of taste response while treating a chronic cough patient with a selective P2X3 modulator. | 2021-10-21 |
20210322433 | NOVEL METHODS - The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia. | 2021-10-21 |
20210322434 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME - Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like. | 2021-10-21 |
20210322435 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound. | 2021-10-21 |
20210322436 | PHARMACEUTICAL COMPOSITION COMPRISING LICARBAZEPINE ACETATE - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 2021-10-21 |
20210322437 | ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS - A method of treating a subject for a brain disease associated with cognitive impairment, including administering to a subject a chemical substance according to GLN-1062 or salt thereof: | 2021-10-21 |
20210322438 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING LUPUS NEPHRITIS - The present disclosure relates to methods for treating lupus nephritis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (INS1007). | 2021-10-21 |
20210322439 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH RTK MUTANT CELLS - Disclosed herein are compositions and methods for treating cancer patients who have been previously treated with one or more chemotherapeutic agents and have developed at least partial resistance to such chemotherapeutic agents. Also disclosed are methods for selecting compounds suitable for treatment of cancer in a patient who has become resistant to an inhibitor of a receptor tyrosine kinase (RTK). | 2021-10-21 |
20210322440 | QUETIAPINE ORAL LIQUID SUSPENSION AND USE THEREOF - The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein. | 2021-10-21 |
20210322441 | CYSTEINYL-PRORESOLVING MEDIATORS THAT PROMOTE RESOLUTION OF INFECTION AND ORGAN PROTECTION - A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH | 2021-10-21 |
20210322442 | LONG-TERM RE-ABSORBABLE SUBCUTANEOUS IMPLANT WITH CONTROLED PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE POLYMER SUBSTANCE RELEASE FOR TREATING ENDOMETRIOSIS - The present invention is aimed at the medical sector and comprises a biodegradable implant of gestrinone in a polymeric matrix. The implant is inserted subdermally and has a continuous release of the asset for an extended period of time. This release aims to guarantee an efficient, constant and prolonged serum level of the drug for the treatment of endometriosis. The implant of the present invention may have only gestrinone in its constitution, but it is preferably formed by particles of gestrinone dispersed homogeneously in a bioerodible and bioabsorbable polymeric matrix. This polymeric matrix can be formed by a polymer or a mixture of polymers. The implants can have any size, shape or structure that facilitates their manufacture and insertion, however, to obtain a more constant and uniform release of the asset, it is necessary to use geometric shapes that maintain their surface area over time. | 2021-10-21 |
20210322443 | NON-BIOCONVERTIBLE C3-SUBSTITUTED PREGNENOLONE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDERS - The present invention relates to the use of non-bioconvertible C | 2021-10-21 |
20210322444 | Methods of Reducing Risk of Preterm Birth - This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth. | 2021-10-21 |
20210322445 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE - The present disclosure provides pharmaceutical compositions of niclosamide that may be administered either orally or by inhalation. These compositions may allow the achievement of a therapeutically effective dose of niclosamide to the lungs or the gastrointestinal tract. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer. | 2021-10-21 |
20210322446 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF - The present invention relates to a pharmaceutical composition comprising a sulfonamide as an inhibitor of Bcl-2/Bcl-xL, especially compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)-phenylaminosulfonyl)-2-trifluoromethyl sulfonyl-anilino)-4-phenylthio-butyl)-piperidine-4-carboxylic acid 3-phosphonopropyl ester or a pharmaceutically acceptable salt thereof and suitable excipients, preferably a pharmaceutical composition in the form of a lyophilized powder. The invention also relates to a method for preparing the pharmaceutical composition. | 2021-10-21 |
20210322447 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES - The present disclosure relates to the transdermal administration of psychedelics, such as psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention and/or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress. | 2021-10-21 |
20210322448 | CER-001 THERAPY FOR TREATING KIDNEY DISEASE - CER-001 for treating kidney disease, and methods for treating a subject having kidney disease with CER-001. | 2021-10-21 |
20210322449 | USE OF MANNURONIC DIACID COMPOSITION IN TREATMENT OF DIABETES - The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes. | 2021-10-21 |
20210322450 | APPLICATION OF COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDE IN ANTI-AGING DRUGS/HEALTHCARE PRODUCTS - The application of a composition containing nicotinamide mononucleotide in anti-aging drugs/healthcare products. Also provided is a preparation method for said composition. NMN can have the function of activating the energy metabolism of an organism and improving the oxidative stress response of the organism and, in synergy with other components, has a good anti-aging effect; each component in the composition is structurally stable, and will not easily deteriorate or be damaged after preparation of a corresponding product; and each component is safe and has no substantial adverse reaction with the human body; the technical problem in the prior art of the difficulty for anti-aging products to have good anti-aging effects whilst being harmless to the human body and having stable product quality is thus solved. | 2021-10-21 |
20210322451 | USE OF MANNOSE 6 PHOSPHATE AND MODIFICATIONS THEREOF FOR MEMORY ENHANCEMENT AND REDUCING MEMORY IMPAIRMENT - Provided are compositions and methods for memory enhancement, including recovery of memory impairment. The compositions and methods relate to mannose-6-phosphate and derivatives of mannose-6-phosphate. The methods relate to administration of M6P or derivatives thereof to individuals in whom memory enhancement is desired. | 2021-10-21 |
20210322452 | COGNITIVE FUNCTION IMPROVING COMPOSITION COMPRISING NOVEL POST FERMENTED TEA-DERIVED KAEMPFEROL-BASED COMPOUND - The present specification relates to a cognitive function decrease improving composition comprising a novel compound separated from post fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, the compound being capable of being widely used in fields related to cognitive functions and nerve cell protection. | 2021-10-21 |
20210322453 | DNA ORIGAMI NANOSTRUCTURES FOR TREATMENT OF ACUTE KIDNEY INJURY - Disclosed herein are methods of treating acute kidney injury. The method can include administering a sufficient amount of a DNA origami nanostructure to a subject afflicted with AKI to increase an excretory function of said subject. In some examples, the the DNA origami nanostructure includes a scaffold strand and a plurality of staple strands, in which the scaffold strand comprises a M13 viral genome having a length of 7249 base pairs; and each staple strand of the plurality of staple strands has a length of about 20 to 60 base pairs. | 2021-10-21 |
20210322454 | HIPPO REGULATION OF CARDIAC VASCULARITY, FIBROSIS, AND INFLAMMATION - Embodiments of the disclosure encompass methods and compositions related to modulating the Hippo pathway to inhibit fibrosis and/or inflammation in a tissue and/or organ of an individual in need thereof. In specific embodiments, the disclosure concerns modulation of LATS1, LATS2, or both, such as providing to the individual an effective amount of one or more agents that increase the levels of LATS1, LATS2, or both in the individual. In specific cases, cardiac fibrosis is treated with effective levels of vector(s) comprising LATS1, LATS2, or both. | 2021-10-21 |
20210322455 | METHODS AND COMPOSITIONS FOR INCREASING THE SUPPRESSIVE FUNCTION OF REGULATORY T-CELLS (TREGS) - Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided. | 2021-10-21 |
20210322456 | BENZIMIDAZOLES THAT ENHANCE THE ACTIVITY OF OLIGONUCLEOTIDES - This disclosure is directed to methods, compounds and compositions for delivering nucleic acids to a cell of interest. In particular, it provides salts that are particularly effective in delivering nucleic acids to cells in the lung for disorders such as cystic fibrosis (CF). | 2021-10-21 |